MediciNova shares surge 11.11% premarket after HC Wainwright initiates coverage with "Buy" rating and price target.

MediciNova surged 11.11% in premarket trading following the initiation of coverage by HC Wainwright & Co., which assigned a 'Buy' rating and set a price target. The firm, led by analyst Lander Egaña Gorroño, highlighted the stock as a new recommendation, signaling strong institutional confidence. Additionally, the company’s participation in the 38th Annual ROTH Conference, scheduled for March 2026, reinforced its visibility among investors, though the immediate price reaction was primarily driven by the analyst upgrade. The combined positive catalysts of a new 'Buy' rating and upcoming investor engagement likely fueled the sharp premarket rally.